Showing results (91-100 of 308) with videos related to

Sort By:
Pageof 31
Cardiology|September 6, 2012
Mortality in the TRACER and ATLAS ACS 2 trials: two more reasons to audit vital records in PLATOVictor L Serebruany, James J DiNicolantonio, Mehmet Mustafa Can
American Journal of Hematology|April 1, 2003
Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage?Victor L Serebruany, Alex I Malinin, David C Sane
American Heart Journal|September 30, 2000
Depression and ischemic heart diseaseC M O'connor, P A Gurbel, V L Serebruany
International Journal of Clinical Practice|March 6, 2021
The FDA and PLATO Investigators death lists: Call for a matchVictor L Serebruany, Jean-Francois Tanguay, Thomas A Marciniak
American Journal of Therapeutics|March 26, 2010
Optimization of anticoagulation with warfarin for stroke prevention: pharmacogenetic considerationsAles Tomek, Vaclav Matoska, Christian Eisert, et al.
Journal of Thrombosis and Thrombolysis|May 29, 2007
Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular diseaseVictor L Serebruany, Alex Malinin, Stephen Ong, et al.
Open Heart|August 2, 2017
Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting SystemVictor Serebruany, Vasily Cherepanov, Seth Fortmann, et al.
International Journal of Cardiology|December 29, 2015
The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfectVictor L Serebruany, Sun Young Choi, Moo Hyun Kim
International Journal of Cardiology|November 27, 2015
Vorapaxar and optimal aspirin dose: The FDA outlookVictor L Serebruany, Seth D Fortmann, Moo Hyun Kim
Pageof 31